Targeting MYC for the treatment of breast cancer: use of the novel MYC-GSPT1 degrader, GT19630.

ABSTRACT:

Background

Since MYC is one of the most frequently altered driver genes involved in cancer formation, it is a potential target for new anti-cancer therapies. Historically, however, MYC has proved difficult to target due to the absence of a suitable crevice for binding potential low molecular weight drugs.

Objective

The aim of this study was to evaluate a novel molecular glue, dubbed GT19630, which degrades both MYC and GSPT1, for the treatment of breast cancer.

Methods

The antiproliferative potential of GT19630 was evaluated in 14 breast cancer cell lines representing the main molecular subtypes of breast cancer. In addition, we also investigated the effects of GT19630 on apoptosis, cell cycle progression, cell migration, and degradation of the negative immune checkpo

SUBMITTER: Tang M 

PROVIDER: S-EPMC11868176 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature